Carbonic anhydrase inhibitors and calcium phosphate stones;Inhibiteurs de l'anhydrase carbonique et lithiase urinaire phosphocalcique

Nephrologie

Volumn 25, Issue 5, 2004, Pages 169-172

  Barbey, Frédéric ^a   Nseir, G ^a   Ferrier, C ^b   Burnier, M ^a   Daudon, M ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Centre de Dialyse   (Switzerland)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Calcium phosphate stone; Carbonic anhydrase; Crystalluria; Hypocitraturia

Indexed keywords

ACETAZOLAMIDE; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE DIBASIC; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; METHAZOLAMIDE; TOPIRAMATE; ZONISAMIDE;

ADULT; ARTICLE; CASE REPORT; CRYSTALLURIA; DRUG INDUCED DISEASE; DYSTONIA; FEMALE; HUMAN; HYPERCALCIURIA; HYPERCHLOREMIC ACIDOSIS; LONG TERM CARE; NEPHROLITHIASIS; PAROXYSMAL HEMIDYSTONIA; RISK FACTOR; STONE FORMATION; URINE PH;

ACETAZOLAMIDE; ADULT; CALCIUM PHOSPHATES; CARBONIC ANHYDRASE INHIBITORS; DYSTONIA; FEMALE; HUMANS; KIDNEY CALCULI;

EID: 4043162670     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Preisig PA, Toto RD, Alpern RJ. Carbonic anhydrase inhibitors. Ren Physiol 1987; 10: 136-59.
2. Swenson ER. Carbonic anhydrase inhibitors and ventilation: A complex interplay of stimulation and suppression. Eur Respir J 1998; 12: 1242-7.
3. Kass MA, Kolker AE, Gordon M, Goldberg I, Gieser DK, Krupin T, et al. Acetazolamide and urolithiasis. Ophthalmology 1981; 88: 261-5.
4. Ahlstrand C, Tiselius HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987; 21: 225-8.
5. Daudon M, Donsimoni R, Hennequin C, Fellahi S, Le Moel G, Paris M, et al. Sex- and age-related composition of 10 617 calculi analyzed by infrared spectroscopy. Urol Res 1995; 23: 319-26.
6. Cohen-Solal F, Abdelmoula J, Hoarau MP, Jungers P, Lacour B, Daudon M. Les lithiases d'origine médicamenteuse. Therapie 2001; 56: 743-50.
7. Daudon M, Jungers P. Drug-induced renal calculi: Epidemiology, prevention and management. Drugs 2004; 64: 245-75.
8. Heller I, Halevy J, Cohen S, Theodor E. Significant metabolic acidosis induced by acetazolamide. Not a rare complication. Arch Intern Med 1985; 145: 1815-7.
9. Brechue WF, Stager JM, Lukaski HC. Body water and electrolyte responses to acetazolamide in humans. J Appl Physiol 1990; 69: 1397-401.
10. Leach WW, Oppelt W. The effect of carbonic anhydrase inhibition on urine formation and electrolyte excretion in the fresh-water turtle (Pseudemys scripta). Comp Biochem Physiol 1969; 29: 1263-6.
11. Hebert LA, Lemann J, Jr, Petersen JR, Lennon EJ. Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 1966; 45: 1886-94.
12. Higashihara E, Nutahara K, Takeuchi T, Shoji N, Araie M, Aso Y. Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: Responses to citrate. J Urol 1991; 145: 942-8.
13. Hamm LL. Renal handling of citrate. Kidney Int 1990; 38: 728-35.
14. Lee DB, Drinkard JP, Rosen VJ, Gonick HC. The adult Fanconi syndrome: Observations on etiology, morphology, renal function and mineral metabolism in three patients. Medicine (Baltimore) 1972; 51: 107-38.
15. Daudon M, Hennequin C, Bader C, Jungers P, Lacour B, Druecke T. Inhibitors of crystallization. Adv Nephrol Necker Hosp 1995; 24: 167-216.
16. Asplin JR, Parks JH, Coe FL. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int 1997; 52: 1602-8.
17. Kaid-Omar Z, Daudon M, Attar A, Semmoud A, Lacour B, Addou A. Correlations entre cristalluries et composition des calculs. Prog Urol 1999; 9: 633-41.
18. Werness PB, Smith LH. Crystalluria. J Crystal Growth 1981; 53: 166-81.
19. Becker BM. Long-term acetazolamide administration in therapy of glaucoma. Arch Ophthalmol 1955; 53: 187-92.
20. Reiss WG, Oles KS. Acetazolamide in the treatment of seizures. Ann Pharmacother 1996; 30: 514-9.
21. Tawil R, Moxley RT, 3rd, Griggs RC. Acetazolamide-induced nephrolithiasis: Implications for treatment of neuromuscular disorders. Neurology 1993; 43: 1105-6.
22. Resor SR, Jr., Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 1990; 40: 1677-81.
23. Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760-87.
24. Leppik IE, Willmore U, Homan RW, Fromm G, Oommen KJ, Penry JK, et al. Efficacy and safety of zonisamide: Results of a multicenter study. Epilepsy Res 1993; 14: 165-73.
25. Shorvon SD. Safety of topiramate: Adverse events and relationships to dosing. Epilepsia 1996; 37 (Suppl. 2): S18-S22.
26. Wasserstein Rak I, Reife RA. Nephrolithiasis during treatment with topiramate. Epilepsia 1995; 36 (Suppl. 3): S153.
27. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol 1977; 95: 1378-82.
28. Carlsen J, Durcan J, Zabriskie N, Swartz M, Crandall A. Nephrolithiasis with dorzolamide. Arch Ophthalmol 1999; 117: 1087-8.
29. Daudon M, Protat MF, Reveillaud RJ, Jaeschke-Boyer H. Infrared spectrometry and Raman microprobe in the analysis of urinary calculi. Kidney Int 1983; 23: 842-50.
30. Pak CY, Fuller C. Idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate. Ann Intern Med 1986; 104: 33-7.
31. Mackenzie A. Acetazolamide-induce renal stone. J Urol 1960; 84: 453-5.
32. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328: 833-8.
33. Trinchieri A, Nespoli R, Ostini F, Rovera F, Zanetti G, Pisani E. A study of dietary calcium and other nutrients in idiopathic renal calcium stone formers with low bone mineral content. J Urol 1998; 159: 654-7.